Investors
We are committed to delivering our strategy and creating value for our shareholders.
Latest News
Latest Events
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Top-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1 around the end of 2022 LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today
Verona Pharma to Host KOL Event on June 16, 2022
LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), today announces it will host an in-person KOL event for analysts and investors on Thursday, June 16, 2022, at 8:00 AM ET, in New York. Verona Pharma’s KOL event will feature presentations
Verona Pharma to Present at Jefferies Healthcare Conference
LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 PM ET / 6:30 PM
Discover More
Verona Pharma
Investor Information
© Verona Pharma plc 2022. All rights reserved